iAnthus Capital HoldingsFRA:2IA EBITDA Margin % is 7.86% as of Mar. 2026. The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, iAnthus Capital Holdings ranks worse than 70.37% on this metric.
iAnthus Capital Holdings (FRA:2IA) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
iAnthus Capital Holdings EBITDA Margin % Related Terms
iAnthus Capital Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, iAnthus Capital Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iAnthus Capital Holdings EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, iAnthus Capital Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where iAnthus Capital Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iAnthus Capital Holdings (FRA:2IA) has a EBITDA Margin % of 7.86% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on iAnthus Capital Holdings and its competitors. According to the industry distribution chart, iAnthus Capital Holdings ranks #672 out of 955 companies in the Drug Manufacturers industry, placing it in the top 70.4%.
Is iAnthus Capital Holdings' EBITDA Margin % too high?
iAnthus Capital Holdings' current EBITDA Margin % is 7.86%. The Drug Manufacturers industry median EBITDA Margin % is 12.39. iAnthus Capital Holdings' value of 7.86% is 36.6% below this industry median. Based on the distribution chart, iAnthus Capital Holdings ranks #672 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does iAnthus Capital Holdings' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, iAnthus Capital Holdings ranks #672 out of 955 companies for EBITDA Margin %. This places iAnthus Capital Holdings in the lower half of its industry. The industry median EBITDA Margin % is 12.39. iAnthus Capital Holdings' value of 7.86% is 36.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. iAnthus Capital Holdings's current EBITDA Margin % of 7.86% is 36.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on iAnthus Capital Holdings and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iAnthus Capital Holdings's current EBITDA Margin % is 7.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iAnthus Capital Holdings stock overvalued right now?
iAnthus Capital Holdings (FRA:2IA) has a current EBITDA Margin % of 7.86%. The current EBITDA Margin % is 7.86% and 36.6% below the Drug Manufacturers industry median of 12.39. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For iAnthus Capital Holdings (FRA:2IA), the current EBITDA Margin % is 7.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
iAnthus Capital Holdings Inc is a vertically-integrated, multi-state owner and operator of licensed cannabis cultivation, processing, and dispensary facilities and a developer, producer, and distributor of branded cannabis products in the United States. Its Cannabis product offerings include flower and trim, products containing cannabis flower and trim (such as packaged flower and pre-rolls), cannabis infused products (such as topical creams and edibles), and products containing cannabis extracts (such as vape cartridges, concentrates, live resins, wax products, oils, and tinctures). The company's reportable operating segments are the Eastern Region, which generates the maximum revenue, and the Western Region.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2IA has been successfully added to your 